

NSW GPs and AMSs

---

## 2026 RSV Maternal and Infant Immunisation Program – Changes to ordering of nirsevimab 50mg

Dear immunisation provider

Thank you for your continued work in implementing the 2026 NSW Respiratory Syncytial Virus (RSV) maternal and infant immunisation program.

Under this program, NSW Health provides the RSV monoclonal antibody (mAb) nirsevimab (Beyfortus™) 50 mg or 100 mg to eligible at-risk infants and children.

Currently GPs and Aboriginal Medical Services (AMSs) are able to order a maximum of 2 doses of nirsevimab 50mg on the [NSW Vaccine Centre webpage](#) directly as part of their monthly routine vaccine order. This is to enable opportunistic vaccination of infants who miss their birth dose of nirsevimab prior to discharge from hospital.

In preparation for the peak RSV season, from 22 April 2026, the maximum number of nirsevimab 50 mg doses that can be ordered will temporarily increase from 2 to 6 doses. Please note that this arrangement is time-limited and based on nirsevimab supply.

The process for ordering **nirsevimab 100mg remains unchanged**. Providers should continue to use the '*nirsevimab order form*' on the NSW Vaccine Centre web portal.

Further information about the NSW RSV maternal and infant immunisation program is available on the [NSW Health webpage](#).

If you have any questions about the program including the nirsevimab ordering process, please contact Immunisation Unit, Health Protection NSW at [MoH-VaccReports@nsw.health.gov.au](mailto:MoH-VaccReports@nsw.health.gov.au).

Regards

Immunisation Unit, Health Protection NSW